Thermo Fisher Scientific Acquires Olink
Thermo Fisher Scientific Inc. is the world leader in serving science, working and researching life science as a clinical research company. They are also a global supplier in analytical instruments, clinical development solutions and more. They work to deliver a cleaner, safer and healthier world with their customers at the forefront of their research.
With the completion of this acquisition of Olink, valued at approximately $3.1 billion with a net of $96 million this enables Olink to become part of Thermo Fisher’s Life Sciences Solutions segment.
Olink will support Thermo Fisher Scientific to level up in the high-growth proteomics market.
Baker McKenzie served as legal counsel for Olink throughout this acquisition.
“The divestment of Olink to Thermo Fisher Scientific is one of the largest public cross-border transactions that we've seen originate from Sweden lately, and a perfect fit for our cross-border capabilities.” says Henric Roth, partner and co-lead of the transaction. “Our teams in Stockholm and New York advised Olink seamlessly with the assistance from experts at Baker McKenzie office's in another ten countries across three continents. Drawing from our vast bench-strength across the globe, we were able to successfully assist the client in what turned out to be an intense transaction with a high-level of regulatory complexity.”
